USP7 and prostate cancer: Here we suggest that the lethal effect obtained by the combined treatment of the PARP inhibitors with the USP7 inhibitors in prostate cancer cells that express CCDC6, and its de-ubiquitinating enzyme USP7, may be considered an “induced synthetic lethality”.